** Shares of Telix Pharmaceuticals rise 2.3% to a record high of A$26.46
** The biopharma co says its Illuccix, a prostate cancer imaging agent, received European approval
** Says all 18 European Economic Area member states agreed Illuccix should be approved
** Co stock on track for a fifth consecutive session of gains, if current trend holds
** Stock up over 7% YTD including session's moves
(Reporting by Rajasik Mukherjee in Bengaluru)
((Rajasik.Mukherjee@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.